Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 6,763

Document Document Title
WO/2007/099553A3
The present invention relates to novel 1,3-dioxane carboxylic acids of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods fo...  
WO/2007/099553A2
The present invention relates to novel 1,3-dioxane carboxylic acids of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods fo...  
WO/2007/096261A3
The present invention is concerned with a novel process for the preparation of compounds of formula (I), wherein R1 and R2 are as defined in the description and claims. The compounds of formula (I) are pharmaceutically active substances.  
WO/2007/096261A2
The present invention is concerned with a novel process for the preparation of compounds of formula (I), wherein R1 and R2 are as defined in the description and claims. The compounds of formula (I) are pharmaceutically active substances.  
WO/2007/083640A1
[PROBLEMS] To provide a drug which has a selective β3 receptor activating effect and is useful in preventing or treating increased urinary frequency and urinary incontinence. [MEANS FOR SOLVING PROBLEMS] It is disclosed that 6-[2-(R)-[(...  
WO/2007/074776A1
The invention aims at providing a simple and easy method by which many kinds of organic chemicals (contaminants) can be efficiently decomposed in a short time and separated and recovered as insoluble matter. Water or soil contaminated wi...  
WO/2007/069773A1
The present invention provides a novel modulator of the TRPV1-receptor function, comprising a compound of the formula; wherein ring A is an optionally substituted carbocycle or heterocycle, ring B is an optionally substituted benzene rin...  
WO/2007/069777A3
Conventional fungicidal compositions have had practical problems such that either a preventive effect or a curative effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases tends ...  
WO/2007/069777A2
Conventional fungicidal compositions have had practical problems such that either a preventive effect or a curative effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases tends ...  
WO/2007/068330A1
The present invention relates to 2-adamantylurea derivatives of formula (I) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and the use of such compounds for the treatment and prevention of m...  
WO/2007/063925A1
Disclosed is a novel and excellent therapeutic or prophylactic agent for nociceptive pain, neuropathic pain, cancer pain, headache, bladder dysfunction or the like, which relies on a preventive activity on capsaicin receptor VR1 activati...  
WO/2007/057703A2
Process for the preparation of statins, in particular atorvastatin via intermediates of Formula (1) and a process for the preparation of said intermediates.  
WO/2007/057703A3
Process for the preparation of statins, in particular atorvastatin via intermediates of Formula (1) and a process for the preparation of said intermediates.  
WO/2007/051762A1
The invention relates to a process for producing trioxane and at least one comonomer for producing (co)polymers on a trioxane basis, in which, in a first step, formaldehyde and at least one comonomer starting material are reacted in aque...  
WO/2007/052831A1
A compound represented by the formula (I): wherein Ar represents a group represented by the formula: (wherein Y represents methylene or an oxygen atom, R1 represents aminosulfonyl, C1-6 alkylaminosulfonyl, C1-6 alkylcarbonylamino or C1-6...  
WO/2007/048717A1
Methodologies for the alpha-monohalogenation of acid sensitive ketones, especially cyclic, acid-sensitive, ketalized ketones. As one approach, the ketone is reacted with a halogen donor compound, e.g., N-chlorosuccinimide, in anhydrous, ...  
WO/2007/039110A2
The invention relates to compounds according to formula (I) or formula (II), wherein R is H or (CHOH)nCH2OH (n= 0, 1 or 2), Sp is -CH-, -CHOH-, -(CH2)n-, -(CH=CH)n-, -(CH=CH-CH2)n,-, -(CH2)n-X-(CH2)o-, -(CH2-X)n-(CH2)o-, -(CH2)n-C(=X)-(C...  
WO/2007/039110A3
The invention relates to compounds according to formula (I) or formula (II), wherein R is H or (CHOH)nCH2OH (n= 0, 1 or 2), Sp is -CH-, -CHOH-, -(CH2)n-, -(CH=CH)n-, -(CH=CH-CH2)n,-, -(CH2)n-X-(CH2)o-, -(CH2-X)n-(CH2)o-, -(CH2)n-C(=X)-(C...  
WO/2007/034909A1
Disclosed is a (3R,5R)-7-amino-3,5-dihydroxyheptanoic acid derivative which is useful as an intermediate for a pharmaceutical. A (3R,5R)-7-amino-3,5-dihydroxyheptanoic acid derivative or a salt thereof can be produced by a process compri...  
WO/2007/032362A1
It is intended to provide a substituted cycloalkene derivative represented by the general formula (I) which has an action of suppressing intracellular signal transduction or cell activation caused by endotoxin and a cell response such as...  
WO/2007/027599A1
This invention provides compounds of Formula (I) having the structure where R1, R2, R3 and A are defined in the specification or a pharmaceutically acceptable salt thereof useful as antibacterial agents. Compounds according to Formula (I...  
WO/2007/015412A1
Disclosed is an organic electroluminescent device (organic EL device) of simple structure which is improved in luminous efficiency and sufficiently secured in driving stability. Also disclosed is a heterocyclic compound used for such an ...  
WO/2007/013201A1
A zinc fluorescent probe that excels in water solubility, enabling observing with high sensitivity of any change of intracellular zinc ion level ratiometrically with the use of a single excited wavelength; a process for producing the sam...  
WO/2007/010514A2
Therefore the present invention relates specifically to the compounds of general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising H, -CnH2n-1, a linear or branched alkyl group h...  
WO/2007/010514A3
Therefore the present invention relates specifically to the compounds of general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising H, -CnH2n-1, a linear or branched alkyl group h...  
WO/2007/000383A1
Biphenyl and phenyl-naphthyl compounds bearing a hydroxamic group, which are endowed with antitumour, and anti-angiogenic activity These compounds are therefore particularly useful for the treatment of drug-resistant tumours.  
WO/2006/134955A1
A compound represented by the general formula (1) or (100), a salt thereof or a hydrate of the compound or salt, which is excellent in cell adhesion-inhibitory effect and cell infiltration-inhibitory effect: (1) (100) wherein R10 represe...  
WO/2006/129036A3
The invention concerns novel 1,2-dioxetane derivatives of general formula (I) as defined in the description, capable of emitting a detectable luminescent signal, their use in a method for detecting and/or quantizing a physical, chemical ...  
WO/2006/129736A1
It is intended to provide an industrially advantageous process for producing a cyclic ester, an industrially advantageous process for producing a cyclic oxyester which is a raw material of poly(hydroxyalkyloxyacetic acid ester), and an i...  
WO/2006/129036A2
The invention concerns novel 1,2-dioxetane derivatives of general formula (I) as defined in the description, capable of emitting a detectable luminescent signal, their use in a method for detecting and/or quantizing a physical, chemical ...  
WO/2006/127235A3
Clarified polyolefins such as polypropylene are used widely to make polymer articles, containers, and the like. Such articles may be manufactured by the injection of molten polymer into a mold or forming device in manufacturing processes...  
WO/2006/123726A1
A pharmaceutical composition comprising (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmacologically acceptable salt thereof and (b) vitamin D or a vitamin D derivative or a pharmacologically acceptable salt thereof; a therapeutic a...  
WO/2006/124899A3
There are disclosed methods for producing derivatives of lactide, including lactamides, propylene glycol, esters, acid anhydrides, modified starches, acrylic acid and pyruvic acid. Also disclosed are methods for producing lactide. Use of...  
WO/2006/124899A2
There are disclosed methods for producing derivatives of lactide, including lactamides, propylene glycol, esters, acid anhydrides, modified starches, acrylic acid and pyruvic acid. Also disclosed are methods for producing lactide. Use of...  
WO/2006/121095A1
A pharmaceutical composition comprising a compound having the general formula (I) or a pharmacologically acceptable salt thereof as the active ingredient: (I) wherein R1 represents a C6-C10 aryl group which may be substituted by a residu...  
WO/2006/120755A1
Provided is a process for producing a cyclic acetal form of 3-oxocyclopentane-1-carboxylic acid more efficiently and industrially advantageously. The process for producing a cyclic acetal form of 3-oxocyclopentane-1-carboxylic acid repre...  
WO/2006/117611A1
The present patent application concerns new compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a saturated nitrogen-containing ring, A is a saturated C1 -4 alkylene and B a C3-4...  
WO/2006/116158A1
Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided, wherein each of R1, R2, R3, R4, y, n, m, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of...  
WO/2006/114432A2
The invention pertains to a method for purifying glycolide comprising the step of distilling crude glycolide under reflux using a distillation column having a ratio S/CxL > 1.1 and S2/C2L > 0.4 m, wherein S stands for the inner surface o...  
WO/2006/114432A3
The invention pertains to a method for purifying glycolide comprising the step of distilling crude glycolide under reflux using a distillation column having a ratio S/CxL > 1.1 and S2/C2L > 0.4 m, wherein S stands for the inner surface o...  
WO/2006/110221A1
Various non-limiting embodiments disclosed herein relate to photochromic materials having extended pi-conjugated systems. For example, various non-limiting embodiments disclosed herein provide a photochromic material, such as an indeno-f...  
WO/2006/106241A1
The invention relates to a compound of formula (I) in which: R1, R2, R3, R4, while being identical or different, each represent an atom or group selected among H, halogen, alkyl, alkoxy, phenyl and cyano; X represents a bond, an oxygen a...  
WO/2006/103527A1
The present invention relates to an aromatic substituted pentadienoic acid amides and there use in combination of specific amounts of aromatic amides i.e. 4-alkyl-5-(substituted phenyl)-2(E),4(E)-pentadienoic acid amides, its geometrical...  
WO/2006/102760A1
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I); wherein Y, L, Z, W, X, Q, R1, R2 and R3 are as defined in the specification.  
WO/2006/098308A1
An anthranilic acid derivative represented by the general formula below or a salt thereof: wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents a phenyl, cycloalkyl or bicyclic heterocyclic group which may...  
WO/2006/095020A1
Compounds of the general formula (I) in which the meanings of the substituents R1 and R2 are as stated in claim 1, have renin-inhibiting properties and can be used as medicines.  
WO/2006/092623A1
A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R1 and R2 together form a group -(CH2)...  
WO/2006/085108A1
Therapeutically active anthranilic acid derivatives of Formula (I) wherein R1, R2, W, Y and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compo...  
WO/2006/081276A1
Compounds of the formula where the variables have the meaning defined in the specification have analgesic and or immunostimulant effect in mammals.  
WO/2006/081332A1
The invention relates to 5-HT6 receptor antagonists. Novel arylamine compounds having the formula: (see formula I) and pharmaceutically acceptable salts and/or esters thereof, wherein - n is 0, 1, 2, 3, or 4; - A, when present is a lower...  

Matches 351 - 400 out of 6,763